Risk-Stratified Therapy for Pediatric Acute Myeloid Leukemia

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Aug 26

PMID 37627199

Authors

Daisuke Tomizawa

Shin-Ichi Tsujimoto

Affiliations

Soon will be listed here.

Abstract

Acute Myeloid Leukemia (AML) is the second most common type of leukemia in children. Recent advances in high-resolution genomic profiling techniques have uncovered the mutational landscape of pediatric AML as distinct from adult AML. Overall survival rates of children with AML have dramatically improved in the past 40 years, currently reaching 70% to 80% in developed countries. This was accomplished by the intensification of conventional chemotherapy, improvement in risk stratification using leukemia-specific cytogenetics/molecular genetics and measurable residual disease, appropriate use of allogeneic hematopoietic stem cell transplantation, and improvement in supportive care. However, the principle therapeutic approach for pediatric AML has not changed substantially for decades and improvement in event-free survival is rather modest. Further refinements in risk stratification and the introduction of emerging novel therapies to contemporary therapy, through international collaboration, would be key solutions for further improvements in outcomes.

Citing Articles

Prognostic factors and outcomes in pediatric acute myeloid leukemia: a comprehensive bibliometric analysis of global research trends.

Rao M, Luo W, Luo C, Wu B, Xu T, Wei Z Front Oncol. 2025; 15:1466818.

PMID: 40034590 PMC: 11873564. DOI: 10.3389/fonc.2025.1466818.

Unveiling unexpected adverse events: post-marketing safety surveillance of gilteritinib and midostaurin from the FDA Adverse Event Reporting database.

Jiang T, Li Y, Zhang N, Gan L, Su H, Xiang G Ther Adv Drug Saf. 2025; 16():20420986241308089.

PMID: 39802043 PMC: 11724423. DOI: 10.1177/20420986241308089.

Intensive chemotherapy with dual induction and ALL-like consolidation for childhood acute myeloid leukemia: a respective report from multiple centers in China.

Li J, Chen Y, Fan Z, Li Q, Liao L, Ke Z Ther Adv Hematol. 2024; 15:20406207241256894.

PMID: 38828002 PMC: 11143855. DOI: 10.1177/20406207241256894.

Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2.

Kikuchi Y, Shimada H, Yamasaki F, Yamashita T, Araki K, Horimoto K Int J Clin Oncol. 2024; 29(5):512-534.

PMID: 38493447 DOI: 10.1007/s10147-024-02497-0.

The efficacy of homoharringtonine in pediatric acute myeloid leukemia: findings from the Chinese Children's Leukemia Group-AML 2015 Study.

Catueno S, Haddad F, Cuglievan B Transl Pediatr. 2024; 13(2):376-379.

PMID: 38455741 PMC: 10915439. DOI: 10.21037/tp-23-536.

References

Buldini B, Rizzati F, Masetti R, Fagioli F, Menna G, Micalizzi C . Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol. Br J Haematol. 2017; 177(1):116-126. DOI: 10.1111/bjh.14523. View

Becton D, Dahl G, Ravindranath Y, Chang M, Behm F, Raimondi S . Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. Blood. 2005; 107(4):1315-24. PMC: 1895393. DOI: 10.1182/blood-2004-08-3218. View

Hasegawa D, Tawa A, Tomizawa D, Watanabe T, Moriya Saito A, Kudo K . Attempts to optimize postinduction treatment in childhood acute myeloid leukemia without core-binding factors: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG). Pediatr Blood Cancer. 2020; 67(12):e28692. DOI: 10.1002/pbc.28692. View

Creutzig U, Zimmermann M, Bourquin J, Dworzak M, von Neuhoff C, Sander A . Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16). Blood. 2011; 118(20):5409-15. DOI: 10.1182/blood-2011-07-364661. View

Gamis A, Alonzo T, Meshinchi S, Sung L, Gerbing R, Raimondi S . Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. J Clin Oncol. 2014; 32(27):3021-32. PMC: 4162498. DOI: 10.1200/JCO.2014.55.3628. View

Tierens A, Bjorklund E, Siitonen S, Marquart H, Wulff-Juergensen G, Pelliniemi T . Residual disease detected by flow cytometry is an independent predictor of survival in childhood acute myeloid leukaemia; results of the NOPHO-AML 2004 study. Br J Haematol. 2016; 174(4):600-9. DOI: 10.1111/bjh.14093. View

Dohner H, Wei A, Appelbaum F, Craddock C, DiNardo C, Dombret H . Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022; 140(12):1345-1377. DOI: 10.1182/blood.2022016867. View

De Moerloose B, Reedijk A, de Bock G, Lammens T, de Haas V, Denys B . Response-guided chemotherapy for pediatric acute myeloid leukemia without hematopoietic stem cell transplantation in first complete remission: Results from protocol DB AML-01. Pediatr Blood Cancer. 2019; 66(5):e27605. DOI: 10.1002/pbc.27605. View

Copelan E, Hamilton B, Avalos B, Ahn K, Bolwell B, Zhu X . Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood. 2013; 122(24):3863-70. PMC: 3854108. DOI: 10.1182/blood-2013-07-514448. View

10.

Heuser M, Freeman S, Ossenkoppele G, Buccisano F, Hourigan C, Ngai L . 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021; 138(26):2753-2767. PMC: 8718623. DOI: 10.1182/blood.2021013626. View

11.

Stevens R, Hann I, Wheatley K, Gray R . Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party. Br J Haematol. 1998; 101(1):130-40. DOI: 10.1046/j.1365-2141.1998.00677.x. View

12.

Hollink I, Zwaan C, Zimmermann M, Arentsen-Peters T, Pieters R, Cloos J . Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML. Leukemia. 2008; 23(2):262-70. DOI: 10.1038/leu.2008.313. View

13.

Sauer M, Lang P, Albert M, Bader P, Creutzig U, Eyrich M . Hematopoietic stem cell transplantation for children with acute myeloid leukemia-results of the AML SCT-BFM 2007 trial. Leukemia. 2019; 34(2):613-624. DOI: 10.1038/s41375-019-0584-8. View

14.

Khoury J, Solary E, Abla O, Akkari Y, Alaggio R, Apperley J . The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022; 36(7):1703-1719. PMC: 9252913. DOI: 10.1038/s41375-022-01613-1. View

15.

Karol S, Alexander T, Budhraja A, Pounds S, Canavera K, Wang L . Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. Lancet Oncol. 2020; 21(4):551-560. PMC: 7153631. DOI: 10.1016/S1470-2045(20)30060-7. View

16.

Gruber T, Gedman A, Zhang J, Koss C, Marada S, Ta H . An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. Cancer Cell. 2012; 22(5):683-97. PMC: 3547667. DOI: 10.1016/j.ccr.2012.10.007. View

17.

Erba H, Montesinos P, Kim H, Patkowska E, Vrhovac R, Zak P . Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023; 401(10388):1571-1583. DOI: 10.1016/S0140-6736(23)00464-6. View

18.

van Weelderen R, Klein K, Harrison C, Jiang Y, Abrahamsson J, Arad-Cohen N . Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood -Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Münster Study Group. J Clin Oncol. 2023; 41(16):2963-2974. PMC: 10414713. DOI: 10.1200/JCO.22.02120. View

19.

de Rooij J, Hollink I, Arentsen-Peters S, van Galen J, Beverloo H, Baruchel A . NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern. Leukemia. 2013; 27(12):2280-8. DOI: 10.1038/leu.2013.87. View

20.

Tomizawa D, Yoshida M, Kondo T, Miyamura T, Taga T, Adachi S . Allogeneic hematopoietic stem cell transplantation for children and adolescents with high-risk cytogenetic AML: distinctly poor outcomes of FUS-ERG-positive cases. Bone Marrow Transplant. 2018; 54(3):393-401. DOI: 10.1038/s41409-018-0273-7. View